Anticancer agent-based marine natural products and related compounds (Q38307526)

2 September 2017

1 reference

title

Anticancer agent-based marine natural products and related compounds (English)

1 reference

2 September 2017

main subject

marine natural product

0 references

1 reference

Jian-Wei Chen

1

1 reference

2 September 2017

Qi-Hao Wu

2

1 reference

2 September 2017

David C Rowley

3

1 reference

2 September 2017

Ammar M Q Al-Kareef

4

1 reference

2 September 2017

Hong Wang

5

1 reference

2 September 2017

publication date

3 January 2015

1 reference

Journal of Asian Natural Products Research

2 September 2017

published in

1 reference

2 September 2017

volume

17

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

199-216

1 reference

Natural products as sources of new drugs over the 30 years from 1981 to 2010

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Lessons from the past and charting the future of marine natural products drug discovery and chemical biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Development of cytarabine prodrugs and delivery systems for leukemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Clinical pharmacokinetics of cytarabine formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

A review of trabectedin (ET-743): a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Synthesis and antitumor activity of simplified ecteinascidin-saframycin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Keyhole limpet hemocyanin (KLH): a biomedical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Keyhole limpet hemocyanin: 9-A CryoEM structure and molecular model of the KLH1 didecamer reveal the interfaces and intricate topology of the 160 functional units

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Crystal structure of a functional unit from Octopus hemocyanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

How aluminum adjuvants could promote and enhance non-target IgE synthesis in a genetically-vulnerable sub-population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

A novel immunomodulatory hemocyanin from the limpet Fissurella latimarginata promotes potent anti-tumor activity in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Immunological potential of Helix vulgaris and Rapana venosa hemocyanins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Structure--activity relationships of the didemnins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Drug discovery from natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Discovery and development of the anticancer agent salinosporamide A (NPI-0052).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Lajollamycin, a nitro-tetraene spiro-beta-lactone-gamma-lactam antibiotic from the marine actinomycete Streptomyces nodosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Antitumor compounds from marine actinomycetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Structurally simplified macrolactone analogues of halichondrin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Eribulin Mesylate: A Promising New Antineoplastic Agent for Locally Advanced or Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

The halichondrins and E7389.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Clinical relevance of P-glycoprotein in drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Multidrug resistance through the spectacle of P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Anti-microtubule 'plinabulin' chemical probe KPU-244-B3 labeled both alpha- and beta-tubulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Structure of the novel steroidal antibiotic squalamine determined by two-dimensional NMR spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Interaction of the antitumor compound cryptophycin-52 with tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Brentuximab Vedotin (SGN-35)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Plitidepsin Cellular Binding and Rac1/JNK Pathway Activation Depend on Membrane Cholesterol Content

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

Cinnabaramides A−G: Analogues of Lactacystin and Salinosporamide from a Terrestrial Streptomycete

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10286020.2014.996140

10.1080/10286020.2014.996140

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference